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During selection of the T cell repertoire, the immune
system navigates the subtle distinction between self-
restriction and self-tolerance, yet how this is achieved
is unclear. Herewedescribe howself-tolerance toward
atrans-HLA (human leukocyteantigen)allotypeshapes
T cell receptor (TCR) recognition of an Epstein-Barr
virus (EBV) determinant (FLRGRAYGL). The recogni-
tion of HLA-B8-FLRGRAYGL by two archetypal TCRs
was compared. One was a publicly selected TCR,
LC13, that is alloreactive with HLA-B44; the other,
CF34, lacks HLA-B44 reactivity because it arises
when HLA-B44 is coinherited in trans with HLA-B8.
Whereas the alloreactive LC13 TCR docked at the C
terminus of HLA-B8-FLRGRAYGL, the CF34 TCR
docked at the N terminus of HLA-B8-FLRGRAYGL,
which coincided with a polymorphic region between
HLA-B8 and HLA-B44. The markedly contrasting foot-
printsof theLC13andCF34TCRsprovidedaportrait of
how self-tolerance shapes the specificity of TCRs
selected into the immune repertoire.
INTRODUCTION
CD8+ T cells expressing ab T cell receptors (TCRs) recognize
peptides bound to major histocompatibility complex class I
(pMHC-I) molecules. Importantly, T cells are restricted such that
they recognize processed peptides onlywhen they are presented
by self-MHC molecules (Zinkernagel and Doherty, 1974). To
ensure protective immunity against pathogens encountered by
the human population, the human leukocyte antigen (HLA) locus
has evolved into the most polymorphic region in the human
genome (Marsh et al., 2005). This polymorphism not only
enhances breadth of ligand binding in outbred populations but
also fundamentally shapes the specificity and size of the host
TCR repertoire, which is matured during thymic development
(Messaoudi et al., 2002). Thus, despitemechanismswithpotential
to generate 1015 different TCRs in humans, positive and negative
T cell selection culls the repertoire to approximately 108 suchTCRs, the diversity of which is required for effective protective
immunity (Arstila et al., 1999). During this selection process, the
T cell repertoire must navigate the fine distinction between self-
restriction and self-tolerance, including tolerance to all host HLA
molecules (Hogquist et al., 1993; Jameson et al., 1995). Precisely
how the HLA genotype of heterozygous individuals influences the
structural specificity of the responding T cell repertoire has not
been visualized at the point of the TCR-pMHC interaction.
As a consequence of thymic selection, TCRs are inherently
cross-reactive, and studies have revealed how TCRs can mold
around a given pMHC-I landscape (and vice versa) (Garcia
et al., 1998; Godfrey et al., 2008; Reiser et al., 2003; Rudolph
et al., 2006). Moreover, structural studies of the TCR-pMHC
complex have provided an understanding of the versatility of
this interaction and include examples of antiviral, antitumor,
autoreactive and alloreactive TCR-pMHC complexes (Archbold
et al., 2008; Clements et al., 2006; Deng and Mariuzza, 2007;
Godfrey et al., 2008). Previously, it has been established
how different TCRs can recognize the same pMHC (Dai et al.,
2008; Ding et al., 1998; Feng et al., 2007), thereby providing
insight into defined interaction motifs as well as the versatility
of the T cell repertoire. The variability in the observed TCR dock-
ing modes is presumably a reflection of the polymorphic nature
of theHLA aswell as the intrinsic variability of the TCR. Neverthe-
less, the TCR and pMHC maintain a rough docking mode, in
which the Va domain and Vb domains are positioned over the
a2-helix and the a1-helix respectively (Godfrey et al., 2008).
Interestingly, the few autoimmune TCRs that have been solved
to date exhibit atypical binding modes in comparison to ‘‘anti-
microbial’’ TCR-pMHC complexes (Hahn et al., 2005; Li et al.,
2005), in that the former tend to focus toward the N-terminal
region of the peptide, whereas the latter are generally focused
more toward the middle or C-terminal end (Deng and Mariuzza,
2007; Nicholson et al., 2005). Moreover, the interactions that the
autoreactive TCRs make with the anitgen (Ag) appear subop-
timal, which correlates with the need for these autoreactive
TCRs to escape negative selection (Deng and Mariuzza, 2007;
Nicholson et al., 2005). Whether these unusual docking modes
are restricted to autoreactive TCRs or also arise in the path-
ogen-driven, self-tolerant repertoire is unclear.
Despite theconstraints ofMHCrestriction, a surprising number
of mature T cells can recognize ‘‘non-self’’ MHC molecules andImmunity 30, 193–203, February 20, 2009 ª2009 Elsevier Inc. 193
Immunity
Avoidance of Self-Reactivityare termed alloreactive. The structural basis of such alloreactivity
is presently limited to one murine system (Archbold et al., 2008).
Specifically, the well-studied 2C TCR adopted two different
docking strategies in recognizing self and non-self MHC mole-
cules, even though there were considerable similarities in the
self and non-self pMHC surfaces (Colf et al., 2007; Rossjohn
and McCluskey, 2007).
Previously, we have explored the in vivo memory cytotoxic T
lymphocyte (CTL) response to an immunodominant HLA-B8-
restricted epitope, FLRGRAYGL, from the latent EBV antigen,
EBNA 3A (Burrows et al., 1990). Remarkably, the immune
response to HLA-B8-FLRGRAYGL is characterized by type
III-biased TCR usage (the reproducible selection of clonal TCR
sequences) identifiable in unrelated HLA-B8+ individuals
(Burrows et al., 1990; Gras et al., 2008; Kjer-Nielsen et al.,
2002a; Turner et al., 2006). We have characterized the structural
and biophysical basis for this biased TCR usage, whereby the
LC13 TCR focused upon the P7Tyr residue of the peptide and
the C-terminal end of the HLA-B8 Ag-binding cleft (Borg et al.,
2005; Kjer-Nielsen et al., 2002b; Kjer-Nielsen et al., 2003).
Conservative substitutions at positions P7Tyr or P8Gly of the
peptide virtually abrogated recognition by the LC13 TCR,
thereby highlighting the specificity of this interaction. Neverthe-
less, the public LC13 TCR displays alloreactivity toward certain
HLA-B44 allotypes (B*4402 and B*4405) (Burrows et al., 1994;
Burrows et al., 1995). Notably, in neither HLA-B8/B*4402 nor
B8/B*4403 heterozygotes is the public LC13 CTL clonotype de-
tected in the mature T cell repertoire (Burrows et al., 1997a;
Burrows et al., 1995), presumably as a result of negative selec-
tion of these T cells. However, a vigorous HLA-B8-restricted
CTL response toward FLRGRAYGL persists in these individuals,
albeit at a slightly lower precursor frequency (Burrows et al.,
1995). Interestingly, these CTLs from HLA-B8+B44+ individuals
now express different T cell receptor gene combinations, and
the fine specificity of the response generally shifts toward either
the P1Phe or the P8Gly residue of FLRGRAYGL, and there is
concomitant loss of B44 reactivity (Burrows et al., 1994; Burrows
et al., 1995). This indicates that the T cell repertoire contains
considerable redundancy in receptors with appropriate speci-
ficity for HLA-B8-FLRGRAYGL, providing an opportunity to
directly examine the structural bases of repertoire selection
dictated by trans-HLA allotypes. The CF34 CTL clone
(TRAV14*01, TRBV11-2*03) represents one such dominant
clonotype of the TCRs in HLA-B8+B44+ individuals whose
T cells exhibit exquisite sensitivity to substitutions at P1Phe and
are tolerant of their endogenous B44 allotype (Burrows et al.,
1994; Burrows et al., 1995).
Here we structurally compare how the TCRs from the arche-
typal LC13 and CF34 anti-viral CTLs interact with the same
HLA-B8-restricted, Ag-specific (FLRGRAYGL) complex. The
LC13 TCR is immunodominant in HLA-B8+ individuals yet allor-
eactive toward HLA-B44, and consequently, LC13 TCR is
deleted from the repertoire in HLA-B8+B44+ individuals. CF34
arises in the context of HLA-B44 as a trans-HLA allele (i.e., it is
present in HLA-B8+B44+ individuals) and therefore is nonreac-
tive with HLA-B44. The observed shift in the pMHC footprint
between these two TCRs provides a compelling picture of how
the requirement for self-tolerance shapes the specificity of the
antiviral T cell repertoire. Namely, the CF34 TCR shifts its194 Immunity 30, 193–203, February 20, 2009 ª2009 Elsevier Inc.footprint to a site of polymorphism between HLA-B8 and HLA-
B44, and in doing so ‘‘sees’’ the differences between these
HLA molecules, thereby providing a basis for the avoidance of
autoreactivity.
RESULTS
Contrasting Specificities for the Viral Determinant
In EBV-infected HLA-B8+B44+ individuals, the HLA-B44 alloreac-
tive, public LC13 CTL clone is no longer selected from the T cell
repertoire and is replaced instead by an oligoclonal T cell reper-
toire, also directed against theHLA-B8-FLRGRAYGLdeterminant
but now lacking reactivity with the B44 allotype (Burrows et al.,
1995). Within this oligoclonal population, the CF34 TCR
(TRAV14*01-TRAJ49, TRBV11-2*03-TRBD2*01-TRBJ2-3) ex-
hibited heightened specificity toward the P1Phe position in CTL
killing assaysbutwas insensitive tomutations at theP8Gly position
(Burrows et al., 1995). In contrast, the public LC13 TCR fromHLA-
B8+B44 individuals was sensitive to amino acid substitutions at
the P8Gly position but not at the P1Phe position (Kjer-Nielsen
et al., 2003). Flow-cytometric analysis with HLA-B8 tetramers
that incorporated analogs of the FLRGRAYGL epitope with
P1Phe and P8Gly substitutions (TLRGRAYGL and FLRGRAYVL,
respectively) confirmed the contrasting specificities of the LC13
and CF34 CTL clones (Figures 1A and 1B). To better understand
the structural basis for this shift in specificity, the CF34 TCR was
expressed, refolded, and purified, allowing comparison to the
LC13 TCR. The recombinant CF34 TCR was functionally intact;
it reacted with conformationally specific anti-TCR monoclonal
antibodies (mAbs), andmoreover native gel-shift analysis demon-
strated that the CF34 TCR could ligate to the HLA-B8-
FLRGRAYGL complex yet did not bind to an irrelevant pMHC
epitope (data not shown). By surface plasmon resonance (SPR)
analysis, the affinity (Kd) of the CF34 TCR for HLA-B8-
FLRGRAYGL was determined to be 8.9 mM, which compared
favorably to a Kd of 15 mM for the LC13 TCR- HLA-B8-
FLRGRAYGL interaction (Borg et al., 2005; Ely et al., 2006; Ely
et al., 2005) (Figure 1C, Table S1). The association constant (Kon)
and dissociation constant (Koff) for the LC13 TCR was 30,950
M1$s1 and 0.56 s1, respectively, which was in agreement
with previous studies (Borg et al., 2005). TheCF34 TCR interacted
with theHLA-B8-FLRGRAYGLcomplexwith a slowerKon of 7,630
M1$s1 and a longer Koff of 0.18 s
1 (calculated from Figure 1C).
Next we compared the sensitivity of the CF34 TCR and the
LC13 TCR to substitutions at positions P1Phe, P7Tyr, and P8Gly
within the FLRGRAYGL peptide (P1Thr, P1Tyr, P7Phe, and P8Val)
bound to HLA-B8. Both the LC13 and CF34 TCRs exhibited
the same high degree of specificity toward the P7Tyr residue;
they showed an 88% and 94% reduction, respectively, in affinity
with HLA-B8FLRGRAFGL in comparison to interaction with the
cognate HLA-B8-FLRGRAYGL (Figures 1C and 1D; also Table
S1). The LC13 TCR was sensitive to substitution at P8Gly; it
was virtually unable to bind to HLA-B8-FLRGRAYVL (Kd > 200
mM; Figure 1D). Alternatively, the affinity of the CF34 TCR for
B8-FLRGRAYVL remained comparable to that of the cognate
interaction. In contrast to this pattern, the affinity of the LC13
TCR for P1Phe mutations was essentially the same as for the
cognate interaction (Figure 1D; also Table S1), whereas CF34
was particularly sensitive to the substitutions at P1Phe and
Immunity
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HLA-B8YLRGRAYGL and HLA-B8-TLRGRAYGL (Figure 1C; also
Table S1). Taken together, these results indicate that although
the LC13 TCR was focused on the C-terminal P7Tyr, the CF34
TCR exhibited heightened specificity toward the N terminus of
the FLRGRAYGL epitope.
Overview of the CF34 TCR-HLA-B8-FLRGRAYGL
Complex
Given the markedly different specificities of the CF34 and LC13
TCRs toward HLA-B8-FLRGRAYGL, we hypothesized that the
CF34 TCR would adopt a quite different footprint to engage
the HLA-B8-FLRGRAYGL complex in comparison to the previ-
ously solved LC13 TCR (Kjer-Nielsen et al., 2003). To examine
this, we purified the CF34 TCR-HLA-B8-FLRGRAYGL complex
and solved the structure at 2.80 A˚ resolution to an Rfac and Rfree
of 22.2% and 27.0%, respectively (see Table 1 and Figures 2A–
2D). The initial experimental phases clearly showed unbiased
Figure 1. Specificities of the CF34 TCR
and LC13 TCRs
HLA-B8 tetramer staining of LC13 (A) and CF34 (B)
cytotoxic T lymphocyte cloneswith differing amino
acid substitutions (underlined) in the FLRGRAYGL
epitope. Numbers in the top right quadrant indi-
cate the percentage of cells costaining with the
CD8 antibody and each of the three different tetra-
mers. This staining pattern was observed in two
individual experiments. Shown is surface plasmon
resonance analysis of graded concentrations of
refolded CF34 (C) and LC13 TCR (D) binding to
HLA-B8-FLRGRAYGL containing substitutions in
the FLRGRAYGL peptide (underlined). Binding
curved for the wild-type peptide FLRGRAYGL (in
black) and variants of the peptide, F1/T in
orange, F1/Y in pink, Y7/F in green, and
G8/V in blue are shown. The biacore experi-
ments were conducted minimally in duplicate.
electron density for the FLRGRAYGL
peptide (data not shown), and moreover,
the electron density at the CF34 TCR-
HLA-B8-FLRGRAYGL interface was
unambiguous.
The CF34 TCR docked at approxi-
mately 58 across the long axis of the
HLA-B8-FLRGRAYGL binding cleft (Fig-
ures 2A and 2C); this docking angle falls
within the range of TCR-pMHC com-
plexes determined to date (Rudolph
et al., 2006) and is similar to the 60 dock-
ing angle of the LC13 TCR-HLA-B8-
FLRGRAYGL interaction (Kjer-Nielsen
et al., 2003) (Figure 2D). However, the
CF34 TCR was located over the N
terminus of the HLA-B8 Ag-binding cleft,
which contrasted the C-terminal docking
of the LC13 TCR on HLA-B8-FLRGRA
YGL (compare Figures 2C and 2D).
Although the CF34 TCR was N-terminally
focused, the CF34 TCR still interacted with positions 65, 69, and
155 of the HLA-B8, which is consistent with the observation that
TCRs invariably interact with these three positions on pMHC-I
(and equivalent pMHC-II) in all TCR-pMHC structures deter-
mined to date (Rudolph et al., 2006; Tynan et al., 2005). The
total buried surface area (BSA) at the CF34 TCR-HLA-B8-
FLRGRAYGL interface was approximately 2180 A˚2, which was
similar to the BSA of the LC13 TCR footprint (2020 A˚2). More-
over, the shape complementarity between the CF34 TCR- and
LC13 TCR- HLA-B8-FLRGRAYGL interfaces were 0.65 and
0.61, respectively (Lawrence and Colman, 1993). Consequently,
CF34 formed many interactions with HLA-B8-FLRGRAYGL
(Table 2), making a total of 127 van der Waals (vdw) interactions,
12 H bonds, and no salt bridges, which compared to 135 vdw
interactions, 14 H bonds, and one salt bridge in the LC13 TCR-
HLA-B8-FLRGRAYGL complex.
Accordingly, the CF34 adopted a markedly shifted N-terminal
footprint on HLA-B8-FLRGRAYLGL in comparison to theImmunity 30, 193–203, February 20, 2009 ª2009 Elsevier Inc. 195
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these differences in footprints, the CF34 TCR engaged the HLA
B8-FLRGRAYGL as effectively as the LC13 TCR.
Comparison of the Footprints
Like the immunodominant LC13 TCR, the CF34-like TCRs found
in HLA-B8+, B44+ EBV+ donors show strong Vb bias in that the
same b chain is observed in a number of CTL clones from unre-
lated individuals (Burrows et al., 1995). Moreover, the sequences
corresponding to theCDR3b loopof theCF34TCR,and toa lesser
degree the CDR3a loop, were observed in a number of CTL
clones from unrelated individuals. The conserved selection
of the length and sequence (16 amino acids, ASSFTWTSG
GATDTQY) of the CDR3b loop, as well as sequence similarities
in the CDR3a loop (AMREDTGNQFY), suggested that they might
play a crucial role in determining the specificity of the CF34 TCR
toward the HLA-B8-FLRGRAYGL complex. The CF34 TCR
comprises TRAV14*01 and TRAJ49 combined with TRBV11-
2*03 and TRBJ2*01, quite distinct from the TRAV26-2*01 and
TRBV7-8*03 gene segments used by the LC13 TCR (Argaet
et al., 1994; Callan et al., 1998). Although their respective Va
chainsonly shared28%sequence identity, their Vbchains shared
Table 1. Data-Collection and Refinement Statistics
Data-Collection Statistics CF34-HLA-B8-FLRGRAYGL
Temperature 100K
Space group I222
Cell Dimensions (a, b, c) (A˚) 111.56, 171.80, 272.69
Resolution (A˚) 72.00-2.80 (2.95-2.80)
Total number of observations 474068 (69644)
Number of unique observations 64663 (9311)
Multiplicity 7.3 (7.9)
Data completeness (%) 99.9 (100)
I/sI 7.9 (1.5)
Rpim
a (%) 12.6 (41.7)
Refinement Statistics
Non-hydrogen atoms
Protein 13494
Water 4
Resolution (A˚) 15.00-2.80
Rfactor
b (%) 22.2
Rfree
b (%) 27.0
Rms deviations from ideality
Bond lengths (A˚) 0.009
Bond angles () 1.258
Ramachandran plot (%)
Most-Favored Region 85.5
Allowed Region 11.8
Generously allowed region 2.3
Values in parentheses are for the highest-resolution shell.
a Rpim = Sh [1/(N 1)]1/2 SijIi(h) – < I(h) > jShSi Ii (h), where I is the observed
intensity and < I > is the average intensity of multiple observations from
symmetry-related reflections.
b Rfactor = Shkl j j Fo j  j Fc j j / Shkl j Fo j for all data except approximately
5%, which were used for Rfree calculation.196 Immunity 30, 193–203, February 20, 2009 ª2009 Elsevier Inc.59% sequence identity, and hence their CDR1b and CDR2b
loops are similar. However, there was no sequence conservation
between the CDR3 loop of the CF34 TCR and that of the LC13
TCR, thereby reflecting the very distinct nature of these TCRs.
The Va and Vb domains of the CF34 TCR contributed 41.7%
and 58.3%, respectively, to the BSA at the HLA-B8-
FLRGRAYGL interface (Figures 2A and 2C), which immediately
provided some insight into the Vb bias of the CF34 TCR. Never-
theless, all six CDR loops of the CF34 TCR contributed to the
interaction, albeit to differing degrees (Figure 2C). Namely,
the germline-encoded CDR1b loop contributed marginally to
the interaction (3.6% BSA), whereas the CDR1a, CDR2a, and
CDR2b loops interacted to a greater extent (13%, 10.7%, and
11.9% BSA, respectively). The footprint was clearly dominated
by the non-germline-encoded CDR3 loops (Table 2), and in
particular the CDR3b loop, which contributed approximately
40% of the BSA at the interface, which was consistent with the
repeated selection of this CDR3b sequence in unrelated individ-
uals. It was notable that, although the Va and Vb domains of
the LC13 TCR contributed roughly equally to the interaction
with HLA-B8-FLRGRAYGL, mutagenesis studies showed that
the non-germline-encoded CDR3 loops of the LC13 TCR domi-
nated the energetic landscape of the interaction with HLA-B8-
FLRGRAYGL (Borg et al., 2005).
As in the LC13 TCR-HLA-B8-FLRGRAYGL interaction (Kjer-
Nielsen et al., 2003), the HLA-B8-FLRGRAYGL complex moved
minimally (rmsd 0.28 A˚ for liganded and nonliganded HLA-B8-
FLRGRAYGL) upon ligation with the CF34 TCR. The peptide
did not change conformation appreciably, and movement in
HLA-B8 was restricted to residues Glu58, Arg62, Glu72, Arg79,
Glu154, Glu166, and Arg170 (data not shown) and either mini-
mized steric hindrance or formed specificity-governing interac-
tions with the CF34 TCR.
Given the very distinct footprints of the CF34 and LC13 TCRs,
the detailed interactions that these TCRs make with their
cognate HLA-B8-FLRGRAYGL target are markedly different
from one another, and the centers of mass of the two TCRs
are separated by 20 A˚, (Figures 2A–2D). Accordingly, the CF34
Va center of mass sits above Glu166 of HLA-B8 (Figures 2C
and 3A), whereas the same point in LC13 sits over Val 152
(compare Figures 2C and 2D). The center of mass for CF34 Vb
is over Thr71 of HLA-B8, whereas for LC13 this resides over
Gly16. The Va domain of the CF34 TCR is positioned over the
a2 helix, and CDR1a and CDR2a exclusively contact HLA-B8,
whereas the CDR3a loop bridged the a1 and a2 helices and con-
tacted the peptide (Figures 2C and 2D). CDR1a sits above the a2
helix of HLA-B8, in which Pro30a nestles between the long
aliphatic side chains of Glu166, Trp167, and Arg170, which
enables Ser28aO to move close enough to hydrogen bond to
Arg170Nh2 as well as enabling Ser31a to make vdw contacts
with Thr163 and Glu166 (Figure 3A, Table 2). The CDR2a loop
also contacts the a2 helix of HLA-B8, such that the aromatic
ring of Tyr59a lies flat against Gly162 and forms vdw contacts
with Glu 166. Unusually, Gln61aOe1 H bonded to Arg108Nh2,
a residue that is not located within the a helices of the Ag-binding
cleft (Figure 3A). CDR3a, which contributes 18% BSA at the
interface, docks above the a1 helix but also bridges across to
the a2 helix, whereby Asp109aOd2 H bonds to Trp167Ne1
(Figure 3B). The CDR3a loop is flanked by the long side chains
Immunity
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Gly111a and Asn112a as well as Gly111aO H-bonding to
Arg62Ne, Nh2 (Figure 3B). The CDR3a loop is flanked by the
long side chains of Arg62 and Glu58 from the HLA-B8 molecule.
These residues make vdw contacts with Thr110a, Gly111a, and
Asn112a of the CDR3a loop, and there are also hydrogen bonds
between Arg62Ne, Nh2 and Gly111aO (Figure 3B).
The Vb domain of theCF34 TCR is positioned over the a1 helix.
Although theCF34TCRCDR1b loop sequence (SGHAT) is similar
to that of the LC13 TCR (SGHVS), the former exclusively con-
tacted the peptide, whereas the latter interacted marginally
with HLA-B8. The CDR2b loop (FQNNGV) of the CF34 TCR
contacts both the peptide and the a1 helix of HLA-B8, whereas
the LC13 TCR CDR2b loop (FQNEAQ) solely contacts the a1
helix of HLA-B8. The CF34 TCR residue Gln 57b, from the
CDR2b loop, makes H bonds and forms vdw interactions with
Thr73 and Thr69, respectively, and these bonds are supple-
mented by the neighboring framework residues, Val66b and
Figure 2. Footprint of CF34 and LC13 TCRs
in Complex with HLA-B8-FLRGRAYGL
Ribbon representation of the CF34 TCR-HLA-B8-
FLRGRAYGL complex (A) and the LC13 TCR-
HLA-B8-FLRGRAYGL complex (B). The TCR
a chain is in pale pink; the b-chain is in pale
blue; HLA-B8 is in gray; and the FLRGRAYGL
peptide is represented as a purple stick. The
footprints of the CF34 TCR (B) and the LC13
TCR (B) on HLA-B8-FLRGRAYGL are shown.
Residues contacted by the CDR loops are
colored in purple (CDR1a), green (CDR2a), yellow
(CDR3a), red (CDR1b), blue (CDR2b), and orange
(CDR3b) in both complexes. The black spheres in
(C) and (D) represent the orientation on the Va
and Vb chains of each TCR on the HLA-
B8-FLRGRAYGL complex, as calculated from
the center of mass.
Asp67b, which interact with Gln65 and
Thr69 (Figure 3C). The CDR3b loop domi-
nated the contacts with the a1 and a2
helices (Figure 3D), as well as the peptide
(discussed below). The 16-amino-acid-
long CDR3b loop, which included a
non-germline-encoded 108Phe-Thr-Trp110
motif, engenders a very broad footprint
that spans most of the length of the
HLA-B8 Ag-binding cleft. There is one H
bond between Ser112bO and Tyr159N
HLA-B8, whereas vdw forces dominate
the remainder of the interactions.
Phe108a and Trp110a make a marked
contribution to the vdw contacts; the
former packs against the aliphatic chain
of Arg151 and Ala150, whereas the latter
is wedged above the a1 helix and inter-
acts with Arg62, Ile66, and Thr69. In addi-
tion, the tip (112Ser-Gly-Gly114) of the
CDR3b loop as well as Thr116b make
a number of vdw contacts (Figure 3D).
Accordingly, the CF34 TCR binds extensively to HLA-B8 in
a manner that is distinct from that of the LC13 TCR; this binding
mode includes differing relative contributions and positioning of
the CDR loops.
Interactions with the Peptide
The FLRGRAYGL epitope protruded minimally from HLA-B8
(Kjer-Nielsen et al., 2002a) and as such contributed only 20%
of the buried surface area of the pMHC interface in both the
LC13 TCR and theCF34 TCR ligated complexes. The side chains
of the peptide that are exposed for TCR contact are P1Phe, P6Ala,
and P7Tyr, as well as the main chain of P4Gly and P8Gly (Figures 3E
and 3F). LC13 TCR focused exclusively on positions P6–P8,
and P7Tyr was fully occluded by CDR1a and both CDR3 loops
(Kjer-Nielsen et al., 2003 and Figure 3E). The small side chains
at positions P6 and P8 were critical for enabling P7Tyr to sit deep
within the LC13 TCR binding pocket as well as for making speci-
ficity-governing interactions (Figure 3E). Thismode of binding wasImmunity 30, 193–203, February 20, 2009 ª2009 Elsevier Inc. 197
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that positions P6–P8 were critical for the interaction, whereas the
P1Phe position was not (Kjer-Nielsen et al., 2003).
Table 2. Contacts between CF34 and HLA-B8-FLRGRAYGL
TCR
Residue MHC Residue
Bond
Type
Gene
Segment
CDR1a Ser38 Arg170 vdw Va
Ser28-O Arg170-Nh2 HB Va
Asp29 Arg170 vdw Va
Pro30 Trp167, Arg170 vdw Va
Ser31 Thr163, Glu166 vdw Va
CDR2a Tyr59 Ala158, Gly162, Glu166 vdw Va
Gln61 Arg108 vdw Va
Gln61-Oe1 Arg108-Nh2 HB Va
CDR3a Asp109 Arg62, Thr163, Trp167 vdw N-Ja
Asp109-Od2 Trp167-Ne1 HB N-Ja
Thr110 Glu58, Tyr59, Arg62 vdw Ja
Gly111 Arg62 vdw Ja
Gly111-O Arg62-Nh2-Ne HB Ja
Asn112 Arg62 vdw Ja
CDR2b Gln57-Oe1 Thr73-Og1 HB Vb
Gln57 Thr69 vdw Vb
FW Val66 Gln65, Thr69 vdw Vb
Val66-O Gln65-Ne2 H Vb
Asp67 Gln65 vdw Vb
Asp67-Od2 Gln65-Ne2 HB Vb
CDR3b Phe108 Ala150, Arg151 vdw VbN
Thr109 Gln155 vdw N
Trp110 Arg62, Ile66, Thr69 vdw N-Db
Ser112 Gln155, Ala158, Tyr159, Thr163 vdw Db
Ser112-O Tyr159-N HB Db
Gly113 Thr163 vdw Db
Gly114 Ala158 vdw Db
Thr116 Glu154, Gln155 vdw Jb
TCR
Residue Peptide Residue
Bond
Type
Gene
Segment
CDR3a Asp109 Phe1 vdw N-Ja
CDR1b Gly28 Tyr7 vdw Vb
Gly28-O Tyr7-OH HB Vb
His29 Tyr7 vdw Vb
Ala30 Ala6, Tyr7 vdw Vb
Ala30-N Tyr7-OH HB Vb
CDR2b Gln57 Arg5, Ala6 vdw Vb
Asn58 Ala6 vdw Vb
Asn58-Od1 Ala6-O HB Vb
CDR3b Phe108 Ala6, Tyr7 vdw VbN
Thr109 Ala6 vdw N
Thr111 Gly4 vdw Db
Subscripted designations indicate the atom involved in hydrogen
bonding. Abbreviations are as follows: FW, Framework residue; HB,
hydrogen bond; V, variable; N, non-germline encoded; D, diversity; J,
joining; vdw, van der Waals cutoff distance% 4 A˚.198 Immunity 30, 193–203, February 20, 2009 ª2009 Elsevier Inc.In contrast, the CF34 TCR interacted with positions P1Phe,
P4Gly, P5Arg, P6Ala, and P7Tyr of the peptide, and contacts were
mediated by the CDR3a, CDR1b, CDR2b, and CDR3b loops
(Figure 3F). P7Tyr is only partially buried (70%) by the CF34 TCR
and makes contacts with the CDR1b and CDR3b. Here,
Phe108b formed vdw contact with P7Tyr, whereas CDR1b con-
tacted P7Tyr via Gly28b, Ala30b, and the main chain of His29b
principally by vdw interactions, but a hydrogen bond is also
formed between the P7Tyr-OH and the main chain of Gly28bO
and Ala30bN (Figure 3F). P6Ala of the FLRGRAYGL peptide is
buried between the three CDR loops of the CF34 TCR Vb chain.
P6Ala forms a large number of vdw interactions and one hydrogen
bond between P6Ala-O and Asn58bOd1 of CDR2b (Table 2). P5Arg
and P4Gly are in contact with the CF34 TCR via their main chain
and interact with CDR2b and CDR3b, respectively. P1Phe is con-
tactedby non-germline-encodedAsp109a, which sits atopP1Phe
to fully bury it. This interaction is stabilized by a hydrogen bond
between Asp109aOd2 and Trp167Ne1 as well as H bonding
between the main chain of Asp109aO H and Arg62Ne of HLA-B8
(Figure 3F). The observed interactions correlate with the ability
of theCF34TCR to accommodate substitutions at theP8Gly while
being sensitive to substitutions at P7Tyr and P1Phe (Figure 1).
Thus, whereas the LC13 TCR focuses on the C-terminal end,
the CF34 TCR is focused on the N-terminal region of the
FLRGRAYGL epitope.
Differing Docking Footprints
The crystal structures of the CF34 and LC13 TCRs in complex
with HLA-B8-FLRGRAYGL allowed us to compare their features
in relation to those of other TCRs that also recognize the same
pMHC. Other examples of previously studied TCRs that can
recognize the same pMHC include the A6 TCR (Garboczi et al.,
1996) and B7 TCR (Ding et al., 1998), which recognize HLA
A2TAX ; B3K506 TCR, YAe62 TCR, and 2W2D TCR, which recog-
nize I-Ab3K (Dai et al., 2008); and 172.10 TCR (Maynard et al.,
2005), 1934.4 TCR, and CL19 TCR (Feng et al., 2007), which
recognize I-AuMBP1-11. Although the detailed interactions within
each of these respective complexes varied, the positioning of
the TCR remained relatively fixed within the particular pMHC
system (Figures 4A–4C). However, the CF34 TCR was obviously
more N-terminally focused with respect to the LC13 TCR in its
recognition of HLA-B8-FLRGRAYGL (Figure 4D).
Of the 19 unique TCR-pMHC-I structures solved to date, only
four TCRs contact the P1 position of the peptide; these four
TCRs are the A6 (Garboczi et al., 1996) and B7 (Ding et al.,
1998) TCR -HLA A2TAX complexes, the scKB5-C20 TCR-H2-
Kb-pKB1 complex (Reiser et al., 2002), and the ELS4 TCR-HLA-
B*3501EPLP complex (Tynan et al., 2007). Thus, the N-terminal
peptide focus of CF34 TCR is somewhat atypical of TCR-
pMHC-I structures. Indeed, the CF34 TCR footprint on HLA-
B8-FLRGRAYGL was more N-terminally focused than any
TCR-pMHC-I complex determined to date and was more remi-
niscent of the N-terminal focus of the class-II-restricted autoim-
mune TCR complexes (Deng and Mariuzza, 2007) (Figure 4E).
Indeed, there are similarities in the docking mode of the CF34
TCR and the 3A6 autoreactive TCR that docked onto HLA DR2
bound to the MBP87-99 peptide (Li et al., 2005), as shown by
the positioning of the different CDR loops over the pMHC land-
scape (compare Figure 4E).
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a little unusual when compared to other antiviral TCR-pMHC
structures and is more similar to autoreactive TCR-pMHC
complexes that exhibited an N-terminal footprint.
A Consensus N-terminal Footprint
Because the CF34 TCR displayed an N-terminal footprint with
sensitivity to substitutions to P1Phe, we established whether this
P1Phe specificity was a general trend for CTL clones in HLA-
B8+B44+ individuals, as indicated previously (Burrows et al.,
1995). To evaluate this, we compared the specificities of an
archetypal LC13-like CTL clone from an HLA-B8+, B44 indi-
vidual and seven CTL clones from HLA-B8+, B44+ individuals
by using cytotoxicity assays and a large panel of analogs of the
FLRGRAYGL peptide with substitutions at P1 and P8. The CTL
clone SC17 from the HLA-B8+ individual expressed a TCR amino
acid sequence identical to that of the LC13 TCR (Argaet et al.,
1994); its TCR showed specificity toward the P8Gly position and
was insensitive to substitutions at theP1Phe position. Conversely,
the CF34 TCR was shown to be insensitive to substitutions at P8
and yet wasmarkedly specific toward P1Phe (Figure 5A). The CTL
clones CF27 and PP36 from HLA-B8+B44+ individuals exhibited
asimilar specificity profile to that of theCF34CTLclone in theCTL
killing assays, suggesting a similar docking footprint among
these CTL clones. However, not all CTL clones from HLA-
B8+B44+ individuals exhibited this ‘‘CF34 TCR specificity
profile.’’ For example, the JL14 and CF8 CTL clones exhibited
a specificity profile that was more ‘‘LC13 TCR-like,’’ whereas
the RL42 CTL clone exhibited sensitivity to substitutions at both
the P1 and P8 positions (Figure 5A). Collectively, these data indi-
cated that although there was a propensity for CTL clones from
HLA-B8+B44+ individuals to focus on the N terminus of the
FLRGRAYGL determinant, other CTLs from these individuals
adopted alternative strategies to avoid self-HLA-B44 reactivity.
To gain an understanding of the relationship between the
N-terminal footprint adopted by the CF34 TCR on HLA-B8-
Figure 3. CF34 Contacts with HLA-B8-
FLRGRAYGL and Comparison to LC13
Contacts between the HLA-B8-FLRGRAYGL
complex and CDR2a (A), CDR3a (B), CDR2b (C),
and CDR3b (D) are shown, and the HLA-B8 and
selected side chains are depicted in gray. CDR
loops and selected side chains are colored as in
Figure 2. Comparison of LC13 and CF34 interac-
tions with the FLRGRAYGL peptide (E and F) are
shown. The CDR loops of LC13 (E) and CF34 (B)
are shown interacting with the exposed side
chains of the FLRGRAYGL peptide in gray. The
indicated CDR loops are colored, and H bonds to
the hydroxyl group of the P7 Tyr are shown as
dotted lines. Residues Phe1 (F1), Tyr7 (Y7), and
Gly8 (G8) of the FLRGRAYGL peptide are labeled.
FLRGRAYGL and the acquisition of toler-
ance to the trans HLA-B44 allotype, we
compared the Ag-binding surfaces of
HLA-B8 and HLA-B44. There are 24 poly-
morphisms between HLA-B44 and HLA-
B8, and only five of these map to the
a helices of the Ag-binding surface (HLA-B8/HLA-B44; Asn/
Thr80, Arg/Leu82, Gly/Arg83, Thr/Leu163 and Trp/
Ser167) (Macdonald et al., 2003; Reid et al., 1996a). These sites
are clustered at the N terminus and the C terminus of the Ag-
binding cleft, as highlighted in cyan in Figure 5B, depicting the
CDR loops of CF34 overlying HLA-B8. Notably, the polymor-
phism that distinguishes HLA-B8 and HLA-B44 at the N-terminal
region (Thr/Leu163 and Trp/Ser167) maps to a sizeable
contact point (12.3% of HLA-B8 buried surface area) with the
CF34 TCR, specifically via the CDR1a, CDR3a, andCDR3b loops
(Figure 5B). In the LC13 complex with HLA-B8-FLRGRAYGL,
neither Trp167 nor Thr163 makes contacts with the TCR,
whereas for CF34 Thr163 is contacted by CDR1a (Ser31a),
CDR3a (Asp109a), and CDR3b (Ser112b and Gly113b). More-
over, Trp167 interacts with CDR1a (Pro30a) and CDR3a
(Asp109a) (Figure 5B). Thus, the CF34 TCR focuses on the N-
terminal region of HLA-B8 and makes extensive contacts in an
area that diverges from theHLA-B44 allotype, creating potentially
unfavorable interactions that are predicted to prevent cross-
reaction with the HLA-B44 molecule.
DISCUSSION
We have provided a basis for how the T cell repertoire maintains
self-pMHC tolerance without compromising immune function in
a naturally out-bred population. Specifically, our findings
demonstrate the structural basis of the avoidance of self-MHC
reactivity in the CTL response to HLA-B8-FLRGRAYGL in
heterozygous HLA-B8+, B44+ individuals (Burrows et al.,
1995). Unlike the prototypic LC13 TCR, the CF34 TCR displayed
heightened specificity for the P1Phe position, and we have
provided a structural basis for this specificity shift. In previous
examples of different TCRs that recognize the same pMHC
(HLA A2TAX, I-AuMBP, and I-Ab3K) (Dai et al., 2008; Ding et al.,
1998; Feng et al., 2007; Garboczi et al., 1996; Maynard et al.,
2005), the comparative modes of TCR docking were broadlyImmunity 30, 193–203, February 20, 2009 ª2009 Elsevier Inc. 199
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Figure 4. Footprints of TCRs that Recognize the Same pMHC Complex
Space-filling models of pMHC complexes recognized bymore than one TCR are shown. (A) Footprint of the A6 and B7 TCRs on the surface of HLA A2TAX. (B) The
footprint of B3K506, YAe62, and 2W2DTCRs on the surface of the I-Ab3K. (C) The footprint of 1934.4, 172.10, and CL19 TCRs on the I-Au MBP1-11. (D) The footprint
of CF34 and LC13 TCR on the HLA-B8-FLRGRAYGL. The CDR loops of the a chain are represented in pink, and the b chain is in blue. The spheres represent the
center ofmass for the Va chain in pink and for the Vb chain in blue. (E) Docking similarity of CF34with autoimmune TCRs bound to pMHC-II. CDR loops (in color) of
the indicated TCRs are shown overlying their cognate pMHC complexes (gray with stick peptides). CF34 and three autoimmune TCRs, 172.10, 3A6, and
OB.1A12, that recognize an MBP peptide bound to a MHC class II molecule are shown. Note that the N-terminal docking focus of the MHC class II-restricted
TCRs resembles the focus of CF34. Similarity in the orientation and conformation of the CDR loops of 3A6 and CF34 is evident.similar within each pMHC group. In contrast, the footprint of the
CF34 TCR is markedly N-terminally shifted with respect to the
LC13 TCR footprint on HLA-B8-FLRGRAYGL. Given that the
CF34 TCR is selected because of the need to avoid self-HLA-
B44 reactivity, the N-terminal footprint of this cognate antiviral
CF34 TCR-HLA-B8-FLRGRAYGL reveals that unusual N-ter-
minal docking footprints are not restricted to autoreactive
TCRs (Deng and Mariuzza, 2007; Hahn et al., 2005; Li et al.,
2005; Nicholson et al., 2005). Conversely, it will be interesting
to evaluate whether autoreactive TCRs can also adopt more
‘‘canonical’’ footprints.
The CF34 footprint on HLA-B8-FLRGRAYGL appears repre-
sentative of a sizeable proportion of the T cell repertoire in
HLA-B8+B44+ individuals, indicating a significant reshaping of
the TCR repertoire selected in the face of the trans HLA-B44
self-complex. This repertoire refocusing exhibits biased Vb
usage in unrelated individuals, as reflected in the CF34 TCR,
and conservation of the CDR3b loop was consistent with its
prominent role in interacting with the FLR peptide. Importantly,
approximately 50% of the CTL clones tested, which display200 Immunity 30, 193–203, February 20, 2009 ª2009 Elsevier Inc.differing Va and/or Vb usage in comparison to CF34 TCR, exhibit
the same specificity profile as the CF34 TCR; specifically, they
are insensitive to substitutions at P8Gly and sensitive to substitu-
tions at P1Phe. However, as judged by the peptide substitution
analysis, not all CTL clones in HLA-B8+B44+ individuals are pre-
dicted to use a footprint similar to that of CF34 TCR, thereby
highlighting the versatility of the T cell repertoire in HLA-
B8+B44+ individuals. The CF34 N-terminal footprint coincided
with the area of polymorphism between HLA-B44 and HLA-
B8, and this probably reflects the need for CF34 to monitor
these differences to avoid self-reactivity toward HLA-B44. It
will be of interest to establish how other CTL clones that exhibit
P8Gly specificity will dock onto HLA-B8-FLRGRAYGL. In this re-
gard, it was notable that the other site of HLA-B8/B44 polymor-
phism maps to the C terminus of the Ag-binding cleft that is
proximal to P8Gly. Although the LC13 TCR forms one vdw inter-
action (via Val30b) with a site (Asn80) that maps to this C-
terminal polymorphic region, alanine-scanning mutagenesis
has indicated that this region is not energetically important for
the LC13 TCR-HLA-B8-FLRGRAYGL interaction (Borg et al.,
Immunity
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the observations in the alloreactive 2C TCR system, where the
2C TCRwas observed to adopt two differing footprints in recog-
nizing the ‘‘cognate’’ complex in comparison to the alloreactive
H2-Ld complex (Colf et al., 2007).
Here, we provide fundamental insights into how the need for
self-tolerance reshapes the TCR repertoire toward a defined viral
determinant thus avoiding self-HLA reactivity. Specifically, to
avoid autoreactivity on HLA-B44, the CF34 focuses on
the HLA-B8 N-terminal region that differs from that of HLA-B44.
Thus, ‘‘seeing thedifferences’’ simultaneouslyprovidesamecha-
nism for the avoidance of autoreactivity and highlights the versa-
tility of the T cell repertoire and TCR-pMHC interaction.
A
B C
Figure 5. Consensus Footprints in HLA-B8+B44+ Individuals
(A) FLR-reactive T cells from HLA-B8+, B44+ individuals can frequently tolerate
peptide amino acid substitutions at P8 but not at P1, suggesting TCR docking
over the peptide N terminus. Recognition by nine different FLR-reactive CTL
clones (listed on the right) of monosubstituted analogs of the EBV peptide
FLRGRAYGL, in which every one of the 20 genetically coded amino acids
were substitutes at P1 or P8. The horizontal axis lists the residue replacing
the parent residue. Target cells were HLA-B8+ PHA blasts, the peptide
concentration was 0.1 mM, and the E:T was 1:1. The SC17 CTL clone was
from an HLA-B8+, B44 individual, and it expresses the well-characterized
LC13 TCR. All other CTL clones are from individuals who coexpress HLA-B8
and HLA-B44. Analogous data were observed when these experiments were
repeated for a second time. The docking footprints of the CF34 TCR (B) and
LC13 TCR (C) are shown with CDR loops in gray overlying HLA-B8-
FLRGRAYGL. Surface polymorphisms that distinguish HLA-B8 and HLA-
B44 are lettered and shown in cyan.EXPERIMENTAL PROCEDURES
Cell Lines
CTL clones were generated from healthy EBV-exposed individuals by agar
cloning as previously described (Burrows et al., 1995). The FLR-reactive CTL
clone SC17 has been previously described (Argaet et al., 1994) and is from
an HLA-B8+, B44 individual (HLA-A1, A31, B8, B51). It expresses the well-
characterized LC13 TCR (Argaet et al., 1994) (Kjer-Nielsen et al., 2003). Other
FLR-reactive CTL clones are from individuals who coexpress HLA-B8 and
HLA-B44, including CF40, CF8, RL42 (Burrows et al., 1995), and PP7 (Burrows
et al., 1997b), which have been previously described. Clone CF40 expresses
the CF34 TCR (Burrows et al., 1995). Clones JL14, CF27, RL12, and PP36
have not been previously described but are known to be FLR reactive but
not cross-reactive with HLA-B44 (data not shown). PHA blasts were generated
and maintained as previously described (Burrows et al., 1995).
Cytotoxicity Assay
CTL clones were tested in duplicate for cytotoxicity in the standard 5 hr chro-
mium release assay (E/T ratio of 1:1) as previously described (McCluskey et al.,
1986). In brief, CTLs were assayed against 51Cr-labeled PHA blast targets that
were pretreated with the peptide (0.1 mM for 1 hr). A beta scintillation counter
(Topcount Microplate; Packard Instrument Co., Meriden, CT) was used for
measuring 51Cr levels in assay supernatant samples. The mean spontaneous
lysis for target cells in culture medium was <20%, and the variation about the
mean specific lysis was <20%.
Protein Expression, Purification, and Crystallization
TheCF34 TCRwas expressed, refolded, and purifiedwith an engineered disul-
fide linkage in the constant domains between the TRAC and TRBC. Both the
a and b chains of the CF34 TCRwere expressed separately as inclusion bodies
in a BL21 Escherichia coli strain. Inclusion bodies were resuspended in 8 M
urea, 20 mM Tris-HCl (pH 8), 0.5 mM Na-EDTA, and 1 mM DTT. CF34 TCR
was refolded by flash dilution in a solution containing 5 M urea, 100 mM Tris
(pH 8), 2 mM Na-EDTA, 400 mM L-arginine-HCl, 0.5 mM oxidized glutathione,
5 mM reduced glutathione, and complete EDTA-free (anti-protease cocktail)
so that any degradation of the a chain would be avoided. The refolding solution
was then dialyzed so that urea would be eliminated. The resulting protein solu-
tion was then purified by gel filtration and HiTrap-Q anion exchange chroma-
tography. The LC13 TCRwas produced under conditions similar to those used
for the CF34 TCR.
Soluble class I heterodimers containing the FLR peptide (or the peptide
mutated) were prepared as described previously (Clements et al., 2002;
Reid et al., 1996b). In brief, the truncated forms (amino acid residues 1–276)
of the HLA-B8 heavy chain and full-length b2-microglobulin (b2 m) were
expressed in Escherichia coli as inclusion bodies. The complex of HLA-B8-
peptide was refolded by dilution of the heavy chain and b2 m inclusion body
preparations into refolding buffer containing a molar excess of peptide ligand.
The refolded complexes were concentrated and purified by anion exchange
chromatography. The complexes were further purified by gel filtration and
HiTrap-Q anion exchange chromatography.
Purified HLA-B8-FLRGRAYGL was mixed with an excess of purified CF34
TCR, and then the CF34-HLA-B8-FLRGRAYGL complex was purified with
a Sephadex-200 gel filtration column.
Crystallization
Crystals of the CF34-HLA-B8-FLRGRAYGL complex were grown by the
hanging-drop, vapor-diffusion method at 20C with a protein/reservoir drop
ratio of 1:1 at a concentration of 11 mg/ml in 10 mM Tris (pH 8) and 150 mM
NaCl. Large rod-shaped crystals grew with 11% PEG 20K, 0.2 M Li2SO4,
0.1 M Tris (pH 8.4), 6 mM CdCl, 4% ethylene glycol, and 4% dioxane.
Data Collection and Structure Determination
The CF34-HLA-B8-FLRGRAYGL crystals were soaked in a cryoprotectant
solution containing mother liquor solution with the PEG concentration
increased to 25% (w/v) and then flash frozen in liquid nitrogen. Data were
collected on the 3BM1 beamline at the Australian Synchrotron, Clayton with
the ADSC-Quantum 210 CCD detector (at 100K). Data were processed withImmunity 30, 193–203, February 20, 2009 ª2009 Elsevier Inc. 201
Immunity
Avoidance of Self-Reactivitythe MOSFLM software (Leslie, 1992) and scaled with SCALA software (Evans,
2006) from the CCP4 suite (CCP4, 1994).
The CF34-HLA-B8-FLRGRAYGL crystal belonged to the space group I222
with unit cell dimensions (Table 1), consistent with two complexes in the asym-
metric unit. The structure was determined by molecular replacement with the
PHASER (Read, 2001) program, for which the LC13 TCR served as the search
model for the TCR (Protein Data Bank accession number, 1KGC) (Kjer-Nielsen
et al., 2002b) and the HLA-B8-FLRGRAYGL served as the MHCmodel without
the peptide (Protein Data Bank accession number, 1M05) (Kjer-Nielsen et al.,
2002a). Manual model building was conducted with the O software (Jones
et al., 1991) followed by maximum-likelihood refinement with the REFMAC
5 program (CCP4, 1994). ‘‘Translation, liberation and screw rotation’’ displace-
ment refinement was used for modeling anisotropic displacements of defined
domains, and medium noncrystallographic symmetry (NCS) restraints were
also used during the refinement process. The TCR was numbered according
to the IMGT unique numbering system (Lefranc et al., 2005), whereby the
CDR1 loops start at residue number 27, the CDR2 loops start at number 56,
and theCDR3 loops start at residue number 105. The final model was validated
with the Protein Data Base validation website, and the final refinement statis-
tics are summarized in Table 1.
All molecular graphics representations were created using PyMol (DeLano,
2002).
Surface Plasmon Resonance Measurement and Analysis
All surface plasmon resonance experiments were conducted at 25C on the
BIAcore 3000 instrument with HBS buffer (10 mM HEPES [pH 7.4], 150 mM
NaCl, and 0.005% surfactant P20). The HBS buffer was supplemented with
1% BSA so that nonspecific binding would be prevented. The human TCR-
specific monoclonal antibody, 12H8 (Borg et al., 2005), was coupled to
research-gradeCM5chipswith standardaminecoupling. For eachexperiment,
CF34 was passed over the flow cell 4 and LC13was passed over the flow cell 2
until approximately 200–400 response unitswere capturedby theantibody. The
other two flow cells were used as control cells for each experiment. The HLA-
B8, either in complex with the wild-type or a variant peptide, was injected
over all four flowcells at a rate of 20ml/min, and therewas a concentration range
of 0.78–200 mM. The final response was calculated by subtraction of the
responseof theantibodyalone from thatof theantibodyCF34orLC13complex.
The antibody surface was regenerated between each analyte injection with
Actisep (Sterogene). All experiments were conducted at least in duplicate.
BIAevaluation Version 3.1 was used for data analysis; the 1:1 Langmuir
binding model was modified to include an additional parameter for the drifting
baseline for the TCR capture by 12H8 was used for calculating the kinetic
constants.
ACCESSION NUMBERS
The coordinates of the CF34-HLA-B8-FLRGRAYGLcomplex have been
deposited in the Protein Data Bank under accession number 3FFC.
SUPPLEMENTAL DATA
Supplemental Data include one table and are available with this article online at
http://www.immunity.com/supplemental/S1074-7613(09)00061-2.
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